How to get GLP-1 weight loss medication online

GLP-1 medications have reshaped clinical weight management, and several FDA-approved options are now available through licensed virtual healthcare providers across the United States. That has made prescription weight-loss treatment more accessible than at any prior point.

Getting a GLP-1 weight-loss medication online involves more than choosing a platform. Eligibility criteria, provider evaluation protocols, pharmacy partnerships, and insurance coverage all shape whether a given program fits a specific patient.

FindDrugs.org is an independent research organization. Its content is based on primary sources, including FDA prescribing information and peer-reviewed clinical outcomes data. It does not accept funding for product promotion and maintains strict neutrality across all drug and provider comparisons.

The sections below break down the available medications and their clinical outcomes, walk through the online prescribing process step by step, and outline how to evaluate a program's legitimacy and costs. For a like-for-like comparison of specific vetted providers, see the best GLP-1 providers guide.

Key Takeaways

• FDA-approved GLP-1 medications for weight management include semaglutide (Wegovy), tirzepatide (Zepbound), liraglutide (Saxenda), and orforglipron (Foundayo), approved in 2026.
• Reported clinical trial weight loss ranges from about 8% for Saxenda to roughly 16% or more for Zepbound over 1 to 1.5 years of treatment.
• The standard online process is a medical intake form, a provider evaluation, a personalized treatment plan, and prescription delivery from an accredited pharmacy.
• Costs depend on self-pay pricing, private insurance, and manufacturer savings cards; eligible Medicare beneficiaries can access select GLP-1 medications for $50 per month through the Medicare GLP-1 Bridge Program, which runs July 1, 2026 through December 31, 2027.
• Before enrolling in any online program, confirm the platform is U.S.-licensed, review insurance and savings options, and verify that ongoing clinical support is available.

What Are GLP-1 Medications for Weight Loss?

GLP-1 medications work by mimicking a natural hormone called glucagon-like peptide-1. This hormone helps control blood sugar, regulate appetite, and influence how the digestive system processes food.

These medications slow gastric emptying, which keeps patients feeling full longer and tends to reduce calorie intake without requiring constant behavioral effort. They also support glucose-dependent insulin release from the pancreas, which helps stabilize blood sugar. The combination of these effects makes GLP-1 medications useful for both weight management and metabolic health.

Several medications are currently FDA-approved for chronic weight management:

• Semaglutide (Ozempic, Wegovy) by Novo Nordisk
• Tirzepatide (Mounjaro, Zepbound) by Eli Lilly and Company
• Liraglutide (Victoza, Saxenda) by Novo Nordisk
• Orforglipron (Foundayo) by Eli Lilly and Company, FDA-approved in 2026

Each works through similar mechanisms but may produce different results depending on the patient.

Clinical Weight Loss Outcomes

Published trial data shows a meaningful range of results across these medications. In the STEP 1 trial, semaglutide (Wegovy) produced about 15% mean weight loss over 68 weeks. In SURMOUNT-1, tirzepatide (Zepbound) produced a mean weight change of -15.0% on the 5 mg dose and -20.9% on the 15 mg dose over 72 weeks, versus -3.1% on placebo. Liraglutide (Saxenda) produced a mean weight change of -7.4% versus -3.0% on placebo at 56 weeks in its labelled trial, less than the semaglutide- or tirzepatide-based options.

For orforglipron, an oral GLP-1 pill, the published Phase 3 ATTAIN-1 trial reported a mean weight change of -11.2% at 72 weeks on the highest dose (36 mg) versus -2.1% on placebo, with 54.6% of patients on that dose losing at least 10% of their body weight.

The FDA-labeled indication for these chronic weight-management medications is adults with a BMI of 30 or higher, or a BMI of 27 or higher when at least one weight-related condition (such as type 2 diabetes or high blood pressure) is present. Whether any individual is an appropriate candidate is a decision for a licensed clinician, not something an online form determines on its own.

Before starting treatment, a care team assesses contraindications. GLP-1 labels carry a boxed warning against use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects across GLP-1 medications include nausea, diarrhea, vomiting, constipation, abdominal pain, and headache; these typically improve as the body adjusts.

Common GLP-1 Medications Available

Several GLP-1 medications are available from manufacturers including Novo Nordisk and Eli Lilly and Company. They help patients manage weight by reducing appetite and supporting blood sugar control, and they are dispensed through licensed U.S. pharmacies and telehealth weight-management programs.

Ozempic and Wegovy (Semaglutide)

Semaglutide works by slowing digestion and reducing hunger signals in the brain. Novo Nordisk produces it for both blood sugar management (Ozempic) and chronic weight management (Wegovy).

Wegovy is the version FDA-approved specifically for weight loss, and it is also approved to reduce the risk of major adverse cardiovascular events in adults with known heart disease who have overweight or obesity. Wegovy's original formulation is a once-weekly subcutaneous injection. In December 2025, the FDA also approved an oral form of Wegovy (oral semaglutide) taken once daily; patients titrate up over several weeks to a 25 mg maintenance dose.

In the STEP 1 trial, semaglutide produced about 15% mean weight loss. Common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, and headache. Clinicians also monitor for temporary worsening of diabetic retinopathy and changes in resting heart rate during treatment. Manufacturer savings programs generally exclude patients enrolled in Medicare or Medicaid.

Liraglutide (Victoza, Saxenda)

Saxenda contains liraglutide and is a daily injection for chronic weight management in adults who meet the labeled BMI criteria. Per its FDA label, Saxenda produced a mean weight change of -7.4% versus -3.0% on placebo at 56 weeks, less than semaglutide- or tirzepatide-based options.

The FDA approved Saxenda for chronic weight management, and telehealth platforms can offer it after a provider evaluates a patient's health factors. Common side effects include:

• Nausea, diarrhea, constipation, and vomiting
• Injection site reactions and headache
• Low blood sugar and fatigue
• Risks of pancreatitis, gallbladder disease, and hypoglycemia

The Medicare GLP-1 Bridge Program does not cover Saxenda. Coverage options for this medication include private health insurance or direct pricing from accredited pharmacies, and prior authorization from an insurer may be required before the prescription is released.

Tirzepatide (Mounjaro, Zepbound)

Tirzepatide acts as both a GIP and a GLP-1 receptor agonist, targeting two distinct metabolic pathways to support weight loss and blood sugar control, which distinguishes it from single-receptor GLP-1 medications.

Zepbound, the FDA-approved weight-loss formulation from Eli Lilly and Company, is administered as a weekly injection. In SURMOUNT-1, tirzepatide produced a mean weight change of -15.0% at the 5 mg dose and -20.9% at the 15 mg dose, versus -3.1% on placebo. The FDA has also approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.

Common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, injection site reactions, fatigue, and GERD. Scheduled visits with a provider help monitor progress and manage reactions throughout treatment.

How to Get GLP-1 Medications Online

Getting GLP-1 medications online involves four sequential steps: completing a medical intake form, undergoing a provider evaluation, receiving a personalized treatment plan, and obtaining the prescription through a licensed pharmacy. Each stage is designed to support clinical safety and regulatory compliance.

Complete a Medical Intake Form

The first step is completing a short health-history questionnaire. This form collects current weight, height, and body mass index (BMI), along with information about weight-related health conditions such as type 2 diabetes or high blood pressure.

You complete the form from home on a secure website. No lab work is required at this stage, and most forms take 10 to 15 minutes to finish. Having your current medication list and recent weight measurements ready before you start speeds up the process.

Your responses help a licensed provider determine whether GLP-1 treatment may be appropriate. Most programs require patients to be at least 18 years old and to reside in an eligible U.S. state. A licensed healthcare provider reviews the intake form before any prescription decision, and the form becomes the foundation for a personalized treatment plan.

Undergo a Provider Evaluation

The next step is a consultation with a licensed clinician, typically through a video visit. The provider reviews your health history, current medications, and weight-loss goals, and assesses your BMI and medical background to determine whether a GLP-1 medication is appropriate. The clinician may request recent lab results or order new tests to confirm treatment safety before proceeding.

Prescribing timelines vary by platform and by the complexity of a patient's medical history, and platforms differ in how thoroughly they evaluate patients before issuing a prescription. Asking your provider directly what timeline to expect for a prescribing decision is a practical step.

If a patient is eligible, the provider can prescribe a GLP-1 medication such as semaglutide, liraglutide, or tirzepatide. Providers may also handle prior-authorization tasks and remain available to adjust the treatment plan as progress develops over time. A prescription is never guaranteed; the decision rests on what is clinically appropriate for each patient.

Receive a Personalized Treatment Plan

An online GLP-1 program builds a treatment plan based on medical history and health goals. A licensed provider reviews the intake form and evaluation results, then determines whether a GLP-1 prescription is clinically appropriate.

A plan may include a specific medication such as semaglutide, liraglutide, or tirzepatide, paired with monthly follow-ups to track progress. Monthly check-ins usually occur through chat or video visits. Lab tests, including HbA1c and metabolic panels, are commonly required for prescription refills; these confirm how well the medication is working and support ongoing safety. Treatment plans are adjusted based on progress, lab findings, and patient feedback.

Prescription Delivery from Accredited Pharmacies

After a provider approves a GLP-1 prescription, the order is sent to an accredited pharmacy of the patient's choice. Accredited pharmacies verify all prescriptions before shipping medications to a patient's home or local store, ensuring that only licensed facilities handle the medication.

Prescriptions are processed through secure channels, giving patients access to FDA-approved medications such as Wegovy, Zepbound, and Foundayo. Delays can often be avoided by confirming a few details before the prescription is submitted:

• Insurance details and any savings-card information entered correctly
• Recent lab results uploaded and available for pharmacy review
• Shipping address on file matches current records
• Signature requirements confirmed with the pharmacy in advance

Lab services tied to prescription refills may carry separate fees, which a provider can arrange as needed.

Choosing the Right Online Program

Selecting an online GLP-1 program means evaluating three core areas: platform legitimacy, pricing and insurance compatibility, and the availability of ongoing clinical support. A program that meets all three provides a more reliable foundation for long-term treatment.

Comparing Specific Programs

Specific platforms differ in price, which medications they offer, which states they serve, age eligibility, and the level of clinical support. Because those details change frequently and vary by provider, this guide does not endorse or rank individual telehealth brands. For an up-to-date, independently scored comparison of GLP-1 telehealth providers, including current pricing and the affiliate relationships we disclose, see the best GLP-1 providers guide.

Verify the Platform's Legitimacy

Every online GLP-1 program should meet clear legal and clinical standards before you consider enrolling. Use the following criteria to evaluate any platform:

1. Confirm the platform is a U.S.-licensed telehealth service. Only U.S.-licensed platforms can prescribe FDA-approved GLP-1 medications, and the company should display its medical licensing clearly.
2. Verify that licensed clinicians conduct individual medical evaluations. Prescriptions must be based on a personal health assessment and are not guaranteed for every patient.
3. Look for a transparent corporate structure, and confirm which clinical entity (for example, a licensed professional medical corporation) employs the prescribers.
4. Verify that testing is handled by independent, third-party laboratories that operate separately from the telehealth company.
5. Confirm that the prescription is fulfilled by an accredited pharmacy that holds proper state licensing and follows medication-distribution regulations.
6. Review the platform's privacy policy to confirm health data is protected under HIPAA and never shared without your consent.
7. Confirm the platform provides ongoing support from qualified healthcare professionals.
8. Check that the program discloses all pricing transparently, including consultation fees, medication costs, and insurance options. Legitimate services do not charge hidden fees.

Review Pricing and Insurance Options

Out-of-pocket costs depend on which program you select, whether insurance covers your treatment, and which manufacturer savings programs apply. In broad terms, patients pay through one of a few channels: self-pay cash pricing, private insurance (where the plan covers weight-loss medications), manufacturer savings cards, or, for eligible Medicare beneficiaries, the Medicare GLP-1 Bridge Program.

Private insurance plans vary widely. Some classify weight-loss medications as elective and exclude them entirely, so checking your Summary of Benefits or asking your HR department before assuming you need self-pay options is a practical first step. Employer coverage also varies by company size. According to KFF's 2025 Employer Health Benefits Survey, 43% of firms with 5,000 or more workers cover GLP-1 medications for weight loss (up from 28% in 2024), compared with 30% of firms with 1,000 to 4,999 workers and 16% of firms with 200 to 999 workers.

Manufacturer savings programs from Novo Nordisk and Eli Lilly and Company can reduce costs for self-paying patients but generally exclude patients enrolled in Medicare or Medicaid. The Medicare GLP-1 Bridge Program, which runs July 1, 2026 through December 31, 2027, allows eligible beneficiaries to access certain GLP-1 medications for $50 per month.

Because specific self-pay prices and promotional windows change frequently and differ by provider, this guide does not list them. For current pricing across vetted programs, see the best GLP-1 providers guide. Before committing, request a detailed pricing breakdown from any program: ask about consultation fees, medication costs, refill procedures, and whether savings programs apply to your insurance type, and get the terms in writing.

Look for Ongoing Support Services

A strong online GLP-1 program provides real-time clinical support and follow-up. Some programs employ board-certified obesity-medicine clinicians who can assist with prior authorization, including for Medicare patients. Support services help patients manage side effects, adjust medications, and monitor eligibility for active savings programs.

A well-structured support program should provide the following:

• Lab test ordering and review (HbA1c and metabolic panels are commonly required for refills)
• The ability to upload recent lab results directly through the platform
• Treatment plan adjustments based on progress and patient feedback
• Clear, separate billing for pharmacy, telehealth, and lab services

Programs that offer comprehensive ongoing support improve the likelihood of consistent treatment adherence and better long-term outcomes.

Conclusion

Getting GLP-1 medications online is more accessible than at any prior point. The process involves a medical intake form, a licensed provider consultation, and prescription delivery through an accredited pharmacy. Costs depend on self-pay pricing, private insurance, manufacturer savings cards, and, for eligible Medicare beneficiaries, the Medicare GLP-1 Bridge Program, which provides $50 monthly access from July 1, 2026 through December 31, 2027.

Evaluating platform legitimacy, confirming insurance or savings eligibility, and securing ongoing clinical support are the key steps before enrolling in any online program. To compare specific, independently scored providers, see the best GLP-1 providers guide, and speak with a healthcare provider to determine whether a GLP-1 medication is appropriate for your medical history and goals.

FAQs

1. What is orforglipron, and how is it different from other GLP-1 medications?

Orforglipron (Foundayo) is an oral GLP-1 receptor agonist taken as a once-daily pill, and its label allows it to be taken with or without food. Most other GLP-1 medications require weekly injections, so this oral delivery method removes the need for needles, addressing a barrier for patients with injection aversion.

2. Where can I get a GLP-1 medication online?

Licensed U.S. telehealth platforms with licensed clinicians can prescribe GLP-1 medications after an online medical evaluation. To compare specific vetted programs, see the best GLP-1 providers guide.

3. Who is eligible for GLP-1 weight-loss medication?

The FDA-labeled indication is adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not take these medications. A licensed clinician makes the final determination based on a full medical history; no online program guarantees a prescription.

4. How do online GLP-1 programs work?

The process involves completing a medical questionnaire, participating in a virtual consultation with a licensed clinician, and obtaining a prescription if it is clinically appropriate.